Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

This study is examining how a class of diabetes medications called SGLT2 inhibitors (such as empagliflozin or dapagliflozin) affects kidney function in people who already have advanced chronic kidney disease. These drugs have shown promise for protecting the kidneys in earlier-stage disease, and this study looks at their effects in more serious cases. **You may be eligible if...** - You are 18 or older - You have advanced chronic kidney disease (eGFR below 20 — meaning kidneys are functioning at less than 20% of normal) - You are not yet on dialysis **You may NOT be eligible if...** - You have polycystic kidney disease (a specific genetic kidney condition) - You have type 1 diabetes - You are already taking an SGLT2 inhibitor - You have had a ketoacidosis episode in the past 3 months - You are allergic to SGLT2 inhibitors, have liver problems, or are pregnant/breastfeeding Talk to your doctor to see if this trial is right for you.